AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
CVSA

Covista Inc. Common Shares (CVSA) fair value

Consumer Defensive · Education & Training Services · NYSE · United States
$131.82+0.15%
Market cap $4.5BNext earnings 2026-10-29Updated Oct 21, 2026
Add earnings to calendarGoogle
Our verdict
Trades 6% below our fair value
Price
$131.82
Model fair valueConfidence: good
$140
Model range
$81.97 to $183
Fair value $140
Price $132
4 models fit Covista Inc. Common Shares and they disagree: 1 of 4 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)Gold82
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionCovista Inc. Common Shares (CVSA)
Fair value (4 models)
$140
ACCE price target
$143
Rating
Fairly valued
Horizon
12 months
Fair value published on 21 Oct 2026, 13:04 CEST; previously $224 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 13:04 CEST.
Price used: $132 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
6.0% below
+6.4% to fair value
ACCE score
77
out of 100
Analysts
75% buy
4 covering
P/E
17.6x
forward 13.6x
1-year return
-13.9%
Dividend yield
0.00%

Covista Inc. Common Shares in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Covista operates in education and training services, and the 9.7% revenue growth, 57.3% gross margin and 19.3% operating margin suggest a business with pricing power and a recurring-style revenue base, though the provided data does not break out which specific courses or platforms drive that. At a 17.0x trailing and 13.6x forward P/E, the market is paying a modest multiple for earnings it expects to grow, which is a reasonable starting point for a defensive compounder. An 18.6% return on equity is the strongest single signal here, showing management is converting shareholder capital into profit at a good rate. The score of 76/100 and absence from any major index mean the name is under-covered by passive flows, which could cut either way on liquidity and volatility. Worth a deeper look to confirm the revenue durability, the source of the margin, and whether the forward earnings estimate is backed by enrolment or contract visibility.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
  • moderate
    Short interest elevated
    Short interest stands at 10.9% of shares. That is a meaningful bet against the stock, so expect sharper moves on any disappointment.

AI research notes

AI-assisted·How I use AIWritten Oct 16, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last twelve months reached $393M, and the stock's free cash flow yield stands at 9.0%.
  • The forward P/E of 12.7x sits well below the sector median forward P/E of 18.1x.
Why it could disappoint
  • Consensus fair value of $127.66 is essentially identical to the $127.24 share price, leaving no margin of safety.
  • Return on invested capital of 8.8% is modest, and the price implies only 1.8% yearly cash flow growth over five years.
  • Revenue growth slowed to 9.7% last year from a 5-year average of 16.6% per year, and enrollment regulation remains a medium risk.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 29, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where CVSA's valuation models land
Price
$131.82
Model fair value
$140
Model range
$81.97 to $183
Fair value $140
Price $132
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish75% buy · 4 covering analysts
● Strong buy 2● Buy 1● Hold 1● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+4.0%
1 month
+7.0%
3 months
+13.8%
6 months
+22.5%
YTD
+27.4%
1 year
-13.9%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
21 Oct 2026, 13:04 CESTRatingFairly valuedfirst publication$128
21 Oct 2026, 13:04 CESTFair value$140$224$128
17 Oct 2026, 00:00 CESTFair value$224$128$127
12 Oct 2026, 00:00 CESTFair value$128$141$129
11 Oct 2026, 00:00 CESTACCE price target$143first publication$129
29 Sept 2026, 00:00 CESTFair value$141$144$121
26 Sept 2026, 00:00 CESTFair value$144$142$124
24 Sept 2026, 00:00 CESTFair value$142$144$123
19 Sept 2026, 00:00 CESTFair value$144$142$126
17 Sept 2026, 00:00 CESTFair value$142$144$126

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full CVSA page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth76Value83Quality80Momentum69Total77
Valuation
Trailing P/E
17.6x
Forward P/E
13.6x
PEG
0.91
P/B
2.90x
EV / Revenue
2.5x
Book value/sh
$42.49
Enterprise value
$4.7B
Profitability
ROE
18.6%
FCF yield
9.14%
ROIC
8.8%
Health and risk
Debt / equity
0.63
Dividend yield
0.00%
Beta
0.65

Price

-13.8% · 1Y

Ask anything about CVSA

Answered from Covista Inc. Common Shares fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 60% of peers
low 6.6x17.6xhigh 30.8x
ROEbetter than 17% of peers
low 17%19%high 422%
Div yieldbetter than 100% of peers
low 0.0%0.0%high 0.0%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
CVSA Covista Inc. Common Shares$131.82$1406% below17.6x18.6%8077
LOPE Grand Canyon Education Inc. Common Stock$165.46$14216% above19.3x31.0%8966
LAUR Laureate Education Inc. Common Stock$38.79$3316% above17.7x29.3%8584
XXI Twenty One Capital Inc. Class A Common Stock$5.61---422.2%5425
TAL TAL Education Group American Depositary Shares$10.46$1945% below6.6x23.7%8778
LRN Stride Inc. Common Stock$80.68$16451% below10.5x20.9%7256
MH McGraw Hill Inc. Common Stock$14.80$2028% below30.8x17.3%5971

Sector report card

Where CVSA ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 13, 2026
    Students at Covista Medical Schools Match or Exceed U.S. MD Peers on USMLE Step 1 First-Time Pass Rates Across MCAT Ranges
  • Business Wire•Oct 1, 2026
    The DAISY Foundation® Names Walden University an Extraordinary Educational Partner
  • Business Wire•Sep 29, 2026
    Covista Announces First Quarter Fiscal Year 2027 Conference Call
8 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 16
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR